{
  "id": 4941543,
  "title": "Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy",
  "url": "https://urgent.news/2026/09/01/andelyn-to-support-manufacturing-scaleup-for-genprexs-diabetes-gene",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-01T21:17:15.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/bioprocessing/andelyn-to-support-manufacturing-scaleup-for-genprexs-diabetes-gene-therapy/"
  },
  "original_language": "en",
  "account": "Genprex has chosen Andelyn Biosciences to help scale up manufacturing for its diabetes gene therapy program. The therapy, which aims to deliver the Pdx1 and MafA genes to the pancreas via an AAV vector, could treat both type 1 and type 2 diabetes. Andelyn will optimize processes, scale up production, and prepare the therapy for clinical trials, leveraging its expertise in AAV development and cGMP manufacturing. In type 1 diabetes, the therapy aims to turn alpha cells into beta-like cells that produce insulin. Preclinical studies in mice have shown restored blood glucose levels and reduced insulin needs. For type 2 diabetes, the therapy could rejuvenate exhausted insulin-producing beta cells. Andelyn's CEO, Matt Niloff, expressed enthusiasm for supporting Genprex's program, while Genprex's CEO, Ryan Confer, highlighted the importance of Andelyn's AAV development experience for IND-enabling studies and clinical evaluation.",
  "summary": "Under the agreement, Andelyn will transition Genprex's adeno-associated virus (AAV)-based diabetes gene therapy candidate with process optimization, scale-up, and IND-enabling and clinical-stage manufacturing to support clinical trials. The post Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [
    "Andelyn Biosciences to scale up manufacturing for Genprex's diabetes gene therapy",
    "Therapy aims to deliver Pdx1 and MafA genes to pancreas via AAV vector",
    "Andelyn's expertise to optimize processes and prepare therapy for clinical trials"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}